First-line combination therapy versus first-line monotherapy for primary hypertension

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 1, 2017, Pages

  Garjón, Javier ^a   Saiz, Luis Carlos ^a   Azparren, Ana ^a   Elizondo, José J ^b   Gaminde, Idoia ^b   Ariz, MA José ^c   Erviti, Juan ^a  

^a Navarre Regional Health Service   (Spain)

^b Universidad Pública de Navarra   (Spain)

^c Navarre Health Service   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR MORTALITY; CLINICAL OUTCOME; COMPARATIVE STUDY; DIASTOLIC BLOOD PRESSURE; HUMAN; HYPERTENSION; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; ADULT; ADVERSE EFFECTS; AGED; CARDIOVASCULAR DISEASE; COMBINATION DRUG THERAPY; DIASTOLE; META ANALYSIS; MORTALITY; SELECTION BIAS; SYSTOLE;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DIASTOLE; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SELECTION BIAS; SYSTOLE;

EID: 85009423421     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010316.pub2     Document Type: Review

References (54)

1. BENEDICT Group. The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics. Controlled Clinical Trials 2003;24(4):442-61. [4766990; PUBMED: 12865039]
2. Ruggenenti P, Fassi A, Ilieva A, Iliev IP, Chiurchiu C, Rubis N, et al. Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. Journal of Hypertension 2011;29:207-16. [4766991; PUBMED: 21243736]
3. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al. Preventing microalbuminuria in type 2 diabetes. New England Journal of Medicine 2004;351(19):1941-51. [4766992; PUBMED: 15516697]
4. Mogensen CE, Viberti G, Halimi S, Ritz E, Ruilope L, Jermendy G, et al. Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension 2003;41(5):1063-71. [4766994; PUBMED: 12654706]
5. Asmar RG, London GM, O'Rourke ME, Mallion JM, Romero R, Rahn KH, et al. Amelioration of arterial properties with a perindopril-indapamide very-low-dose combination. Journal of Hypertension. Supplement 2001;19(4):S15-20. [4766996; PUBMED: 11848258]
6. Asmar RG, London GM, O'Rourke ME, Safar ME. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension 2001;38(4):922-6. [4766997; PUBMED: 11641310]
7. London GM, Asmar RG, O'Rourke MF, Safar ME. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. Journal of the American College of Cardiology 2004;43(1):92-9. [4766998; PUBMED: 14715189]
8. Mallion JM, Chamontin B, Asmar R, De Leeuw PW, O'Brien E, Duprez D, et al. Twenty-four-hour ambulatory blood pressure monitoring efficacy of perindopril/indapamide first-line combination in hypertensive patients: the REASON study. American Journal of Hypertension 2004;17(3):245-51. [4766999; PUBMED: 15001199]
9. Brown MJ, McInnes GT, Papst CC, Zhang J, MacDonald TM. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet 2011;377(9762):312-20. [4767001; PUBMED: 21236483]
10. Ruggenenti P, Fassi A, Ilieva A, Iliev IP, Chiurchiu C, Rubis N, et al. Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. Journal of Hypertension 2011;29:207-16. [4767003; PUBMED: 21243736]
11. Ruggenenti P, Lauria G, Iliev IP, Fassi A, Ilieva AP, Rota S, et al. Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND) randomized clinical trial. Hypertension 2011;58(5):776-83. [4767005]
12. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ (Clinical Research Ed.) 1992;304(6824):405-12. [4767007; PUBMED: 1445513]
13. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. New England Journal of Medicine 2008;358(15):1547-59. [4767009]
14. Dahlof B, Gosse P, Gueret P, Dubourg O, de Simone G, Schmieder R, et al. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. Journal of Hypertension 2005;23(11):2063-70. [4767011; PUBMED: 16208150]
15. Zhang JL, Qin YW, Zheng X, Qiu JL, Zhao XX, Zou DJ. Combination therapy with angiotensin-converting enzyme inhibitors and indapamide impairs glucose tolerance in Chinese hypertensive patients. Blood Pressure 2010;19(2):110-8. [4767013; PUBMED: 20053144]
16. Derosa G, Cicero AF, Carbone A, Querci F, Fogari E, D'Angelo A, et al. Olmesartan/amlodipine combination versus olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients. Clinical and Experimental Hypertension 2013;35(5):301-7. [4767015; PUBMED: 22954201]
17. Derosa G, Bonaventura A, Romano D, Bianchi L, Fogari E, D'Angelo A, et al. Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study. Journal of the American Society of Hypertension 2014;8(6):422-8. [4767017; PUBMED: 24836352]
18. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356(9227):366-72. [4767019; PUBMED: 10972368]
19. Fuchs FD, Fuchs SC, Moreira LB, Gus M, Nobrega AC, Poli-de-Figueiredo CE, et al. A comparison between diuretics and angiotensin-receptor blocker agents in patients with stage I hypertension (PREVER-treatment trial): study protocol for a randomized double-blind controlled trial. Trials 2011;12:53. [4767021; PUBMED: 21349192]
20. Fuchs FD, Scala LC, Vilela-Martin JF, de Mello RB, Mosele F, Whelton PK, et al. Effectiveness of chlorthalidone/amiloride versus losartan in patients with stage I hypertension: results from the PREVER-treatment randomized trial. Journal of Hypertension 2016;34(4):798-806. [4767022; PUBMED: 26938814]
21. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. New England Journal of Medicine 2003;349(20):1893-906. [4767024]
22. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. New England Journal of Medicine 2008;359(23):2417-28. [DOI: 10.1056/NEJMoa0806182]
23. Parving HH, Brenner BM, McMurray JJV, de Zeeuw D, Haffner SM, Solomon SD, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. New England Journal of Medicine 2012;367(23):2204-13. [DOI: 10.1056/NEJMoa1208799]
24. Bakris G, Sarafidis P, Agarwal R, Ruilope L. Review of blood pressure control rates and outcomes. Journal of the American Society of Hypertension 2014;8(2):127-41. [PUBMED: 24309125]
25. Chen N, Zhou M, Yang M, Guo J, Zhu C, Yang J, et al. Calcium channel blockers versus other classes of drugs for hypertension. Cochrane Database of Systematic Reviews 2010, Issue 8. [DOI: 10.1002/14651858.CD003654.pub4]
26. Daskalopoulou SS, Rabi DM, Zarnke KB, Dasgupta K, Nerenberg K, Cloutier L, et al. The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Canadian Journal of Cardiology 2015;31(5):549-68. [DOI: 10.1016/j.cjca.2015.02.016]
27. European Medicines Agency. Combined use of medicines affecting the renin- angiotensin system (RAS) to be restricted - CHMP endorses PRAC recommendation, 2014. www.ema.europa.eu/docs/en_GB/document_library/Press_release/2014/05/WC500167421.pdf (accessed 5 August 2015).
28. IECS (Institute of Clinical Effectiveness and Health Policy). EROS Early Review Organizing Software. Version 2.0. Buenos Aires: IECS (Institute of Clinical Effectiveness and Health Policy), 2009.
29. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal 2013;34(28):2159-219.
30. US Drugs, Food Administration. ACE inhibitors: dual blockade of the RAS, 2014. www.fda.gov/Safety/MedWatch/SafetyInformation/ucm418829.htm (accessed 5 August 2015).
31. Gradman AH, Basile JN, Carter BL, Bakris GL, Materson BJ, Black HR, et al. Combination therapy in hypertension. Journal of the American Society of Hypertension 2010;4(2):90-8. [PUBMED: 20400053]
32. Heran BS, Chen JMH, Wang JJ, Wright JM. Blood pressure lowering efficacy of potassium-sparing diuretics (that block the epithelial sodium channel) for primary hypertension. Cochrane Database of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/14651858.CD008167.pub3]
33. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available fromhandbook.cochrane.org.
34. Hilleman DE, Ryschon KL, Mohiuddin SM, Wurdeman RL. Fixed-dose combination vs monotherapy in hypertension: a meta-analysis evaluation. Journal of Human Hypertension 1999;13(7):477-83. [PUBMED: 10449213]
35. International Conference on Harmonisation. Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. ICH Harmonised Tripartite Guideline CPMP/ICH/377/95. London: European Medicines Agency, 1995.
36. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311(5):507-20. [DOI: 10.1001/jama.2013.284427; PUBMED: 24352797]
37. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ (Clinical Research Ed.) 2003;326(7404):1427. [PUBMED: 12829555]
38. Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technology Assessment (Winchester, England) 2003;7(31):1-94. [PUBMED: 14604498]
39. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ (Clinical Research Ed.) 2009;338:b1665. [PUBMED: 19454737]
40. Liu Y, Chen K, Kou X, Han Y, Zhou L, Zeng C. Aliskiren and amlodipine in the management of essential hypertension: meta-analysis of randomized controlled trials. PLoS One 2013;8(7):e70111. [PUBMED: 23922924]
41. Lv Y, Zou Z, Chen GM, Jia HX, Zhong J, Fang WW. Amlodipine and angiotensin-converting enzyme inhibitor combination versus amlodipine monotherapy in hypertension: a meta-analysis of randomized controlled trials. Blood Pressure Monitoring 2010;15(4):195-204. [PUBMED: 20512032]
42. Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ (Clinical Research Ed.) 2013;346:f360. [PUBMED: 23358488]
43. National Collaborating Centre for Chronic Conditions. Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update). London: Royal College of Physicians, 2008.
44. National Clinical Guideline Centre. Hypertension: the Clinical Management of Primary Hypertension in Adults. London: National Clinical Guideline Centre, 2011.
45. Benetos A, Labat C, Rossignol P, Fay R, Rolland Y, Valbusa F, et al. Treatment with multiple blood pressure medications, achieved blood pressure, and mortality in older nursing home residents: the PARTAGE study. JAMA Internal Medicine 2015;175(6):989-95. [PUBMED: 25685919]
46. Povoa R, Barroso WS, Brandao AA, Jardim PC, Barroso O, Passarelli O Jr, et al. I Brazilian position paper on antihypertensive drug combination. Arquivos Brasileiros de Cardiologia 2014;102(3):203-10. [PUBMED: 24714792]
47. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
48. Ruzicka M, Leenen FH. Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension. Drugs 2001;61(7):943-54. [PUBMED: 11434450]
49. Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Internal Medicine 2015;175(5):827-34. [PUBMED: 25798731]
50. Sood N, Reinhart KM, Baker WL. Combination therapy for the management of hypertension: a review of the evidence. American Journal of Health-System Pharmacy 2010;67(11):885-94. [PUBMED: 20484210]
51. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11, 000 participants from 42 trials. American Journal of Medicine 2009;122(3):290-300. [PUBMED: 19272490]
52. Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Mbewu A, Opie LH. Beta-blockers for hypertension. Cochrane Database of Systematic Reviews 2012, issue 11. [DOI: 10.1002/14651858.CD002003.pub4; CD002003]
53. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD001841.pub2]
54. Xue H, Lu Z, Tang WL, Pang LW, Wang GM, Wong GWK, et al. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database of Systematic Reviews 2015, Issue 1. [DOI: 10.1002/14651858.CD008170.pub2]